Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: The impact of impaired sleep quality on symptom change and future exacerbation of chronic obstructive pulmonary disease

Fig. 3

Comparison of the symptoms improvement between different GOLD group or different main inhalation therapy in COPD patients with different sleep quality

MCID response rate of different GOLD group in COPD patients. (B) MCID response rate of different GOLD group in COPD patients with different sleep quality. (C) MCID response rate of different inhaled medication in COPD patients. (D) MCID response rate of different inhaled medication in COPD patients with different sleep quality. (E) MCID response rate of different GOLD group in treatment of ICS/LABA. (F) MCID response rate of different GOLD group in treatment of ICS/LABA/LAMA. ns indicates P-values > 0.05, *indicates P-values < 0.05, **indicates P-values < 0.01,*** indicates P-values < 0.001

Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; IQR, interquartile range; LABA, long-acting β-2-agonist; LAMA, long-acting muscarinic antagonist; MCID, minimum clinically important difference.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us